Low-Dose CDK4/6 Inhibitors Induce Presentation of Pathway Specific MHC ligands as Targets for Cancer Immunotherapy

Supporters

Support the authors with ResearchCoin

Tip RSC

Preprint Server

Topics

Biology

Biochemistry

Cancer Oncology

Immunology

Genetics

Show all topics

DOI

10.1101/2020.06.18.157800

License

CC-BY

Other Formats

PDF